|
목적 : To determine the influence of rebound macular edema after intravitreal bevacizumab on visual outcome and changes of photoreceptor integrity in eyes with macular edema (ME) secondary to branch retinal vein occlusion (BRVO)
방법 : This retrospective study included 46 eyes treated with intravitreal bevacizumab for ME secondary to BRVO. The patients were divided into two groups according to rebound status: Group I (8 eyes) underwent rebound and group II underwent no rebound. A rebound ME was defined as a ≥110% increase in the foveal thickness or a foveal thickness ratio≥110% (foveal thickness at the recurrence/foveal thickness at the baseline X100). The changes in best corrected visual acuity (BCVA, logMAR) and photoreceptor integrity after intravitreal bevacizumab were compared between two groups for 6 month follow up.
결과 : Mean BCVA was significantly improved from logMAR 0.88±0.64 to 0.50±0.49 at month 6 in group I and from logMAR 0.62±0.43 to 0.25±0.27 at month 6 in group II. No significant difference in visual changes was found between two groups during follow-up. There was no significant difference in the proportion of eyes with intact inner segment/outer segment (IS/OS) line between two groups at the baseline. However, at month 6, group I showed less proportion of eyes (3 eyes, 38 %) with intact IS/OS line than group II (29 eyes, 76 %)(p=0.04).
결론 : The recurrence as rebound ME may bring unfavorable influences on restoration of photoreceptor integrity after treatment in ME secondary to BRVO. Therefore the effort to reduce the frequent recurrence of rebound ME may be required for better visual outcome.
|